BiotechTube

peficitinib + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Mar 23, 2010 → Jul 27, 2011

NCT ID
NCT01096862

About peficitinib + Placebo

peficitinib + Placebo is a phase 2 stage product being developed by Astellas Pharma for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01096862. Target conditions include Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Psoriasis were approved

Approved (20) Terminated (3) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Ilumya Injectable ProductSun PharmaceuticalApproved
✅TildrakizumabSun PharmaceuticalApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT01565655Phase 2Completed
NCT01649999Phase 2Completed
NCT01096862Phase 2Completed
NCT01225224Phase 1Completed

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + PlaceboDr. Reddy's LaboratoriesPhase 2
32
Ixekizumab + PlaceboEli LillyPhase 2
35
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
21
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
27
IxekizumabEli LillyPhase 3
40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
40
Placebo + BaricitinibEli LillyPhase 2
35
CT-P43 + StelaraCelltrionPhase 3
40
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
AMG 139AstraZenecaPhase 1
29
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 2
35
Tacrolimus CreamAstellas PharmaPhase 3
40
alefaceptAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40
alefaceptAstellas PharmaApproved
43